| Rx0000064 |
CASPER PHARMA, LLC |
03/31/2022 |
70199002611 |
Intramuscular Solution 50000 UNIT/ML (Package size - 2ML single dose vial) |
01/25/2022 |
455.00 |
575.00 |
None |
Single Source Drug |
None |
1 |
Casper Pharma makes pricing decisions regarding the WAC price of a medication after careful consideration of a number of factors, including but not limited to a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) overall general administration, research and development costs. |
None |
None |
1 |
06/29/2018 |
Pfizer |
None |
1 |
None |
100.00 |
100.00 |
2006 |
221.35 |
None |
None |
| Rx0000110 |
Chartwell Rx LLC |
03/31/2022 |
62135019222 |
Calcium Acetate Oral Tablet 667 MG 200 Tablet Bottles |
01/03/2022 |
159.64 |
300.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
12/01/2019 |
Cipla |
None |
1 |
None |
140.36 |
140.36 |
2019 |
140.36 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
09/30/2022 |
62135020690 |
methIMAzole Oral Tablet 10 MG 90ct |
08/31/2022 |
110.14 |
270.00 |
None |
Non-innovator Multiple Source Drug |
4464 |
None |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/04/2021 |
CASI PHARMACEUTICALS |
None |
1 |
None |
159.86 |
159.86 |
2001 |
159.86 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
09/30/2022 |
62135020618 |
methIMAzole Oral Tablet 10 MG, 180ct |
08/31/2022 |
220.28 |
540.00 |
None |
Non-innovator Multiple Source Drug |
1800 |
None |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/04/2021 |
CASI PHARMACEUTICALS |
None |
1 |
None |
319.72 |
319.72 |
2001 |
319.72 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
09/30/2022 |
62135020518 |
methIMAzole Oral Tablet 5 MG, 180ct |
08/31/2022 |
309.97 |
495.00 |
None |
Non-innovator Multiple Source Drug |
4608 |
None |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/04/2021 |
CASI PHARMACEUTICALS |
None |
1 |
None |
185.03 |
185.03 |
2001 |
185.03 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
09/30/2022 |
62135020590 |
methIMAzole Oral Tablet 5 MG, 90ct |
08/31/2022 |
154.98 |
247.50 |
None |
Non-innovator Multiple Source Drug |
9144 |
None |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/04/2021 |
CASI PHARMACEUTICALS |
None |
1 |
None |
92.52 |
92.52 |
2001 |
92.52 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
03/31/2022 |
62135096001 |
Sulfasalazine Oral Tablet 500 MG 100 Tablet Bottles |
01/12/2022 |
100.00 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/01/2020 |
AVET/Heritage |
None |
1 |
None |
100.00 |
100.00 |
2021 |
100.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
03/31/2022 |
62135096010 |
Sulfasalazine Oral Tablet 500 MG 1000 Tablet Bottles |
01/12/2022 |
1000.00 |
2000.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/01/2020 |
AVET/Heritage |
None |
1 |
None |
1000.00 |
1000.00 |
2021 |
1000.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
03/31/2022 |
62135096031 |
Sulfasalazine Oral Tablet 500 MG 300 Tablet Bottles |
01/12/2022 |
300.00 |
600.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/01/2020 |
AVET/Heritage |
None |
1 |
None |
300.00 |
300.00 |
2021 |
300.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000110 |
Chartwell Rx LLC |
03/31/2022 |
62135096005 |
Sulfasalazine Oral Tablet 500 MG 500 Tablet Bottles |
01/12/2022 |
500.00 |
1000.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
11/01/2020 |
AVET/Heritage |
None |
1 |
None |
500.00 |
500.00 |
2021 |
500.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts. |
| Rx0000139 |
Chiesi USA |
03/31/2022 |
10122051001 |
Curosurf® 1.5ml 120 mg/1.5 mL (80 mg/mL) |
02/01/2022 |
14.82 |
508.70 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000139 |
Chiesi USA |
03/31/2022 |
10122051003 |
Curosurf® 3.0ml 240 mg/3 mL (80 mg/mL) |
02/01/2022 |
29.22 |
1003.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287002004 |
CaroSpir, Suspension, Oral, 25mg/5mL, 118 mL in 1 BOTTLE |
10/17/2022 |
34.35 |
415.50 |
10/28/2036 |
Single Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287002001 |
CaroSpir, Suspension, Oral, 25mg/5mL, 473 mL in 1 BOTTLE |
10/17/2022 |
137.15 |
1665.00 |
10/28/2036 |
Single Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287001430 |
Oracit, Cirtic Acid and Sodium Citrate, 640mg/5mL, Solution, Oral 10 Bottle Unit Dose in 1 Carton > 30 mL in 1 Bottle |
10/17/2022 |
5.80 |
44.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287002410 |
POTASSIUM PHOSPHATES, Injection, 300 mg/mL, 175 mg/mL, 10 VIAL, in 1 CARTON > 15 mL in 1 VIAL |
12/01/2022 |
168.00 |
299.00 |
04/19/2039 |
Single Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287000660 |
Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 10 BOTTLE in 1 CARTON 60 mL in 1 BOTTLE, |
12/01/2022 |
42.00 |
243.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287000604 |
Sodium Polystyrene Sulfonate, suspension, 15g/60mL, 120 mL in 1 BOTTLE |
12/01/2022 |
18.08 |
108.48 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2022 |
46287000601 |
Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 473 mL in 1 BOTTLE |
12/01/2022 |
44.52 |
196.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increasing costs related to inflationary environment – materials, shipping, labor, overheads |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510011660 |
NUCYNTA ER, 100mg, tablet, 60 pack |
01/01/2022 |
137.73 |
1055.90 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
835.46 |
760.20 |
2011 |
269.40 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510017460 |
NUCYNTA ER, 150mg, tablet, 60 pack |
01/01/2022 |
177.69 |
1362.29 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1077.89 |
980.79 |
2011 |
346.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510023260 |
NUCYNTA ER, 200mg, tablet, 60 pack |
01/01/2022 |
225.57 |
1729.35 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1368.32 |
1245.06 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510029160 |
NUCYNTA ER, 250mg, tablet, 60 pack |
01/01/2022 |
282.21 |
2163.60 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1711.91 |
1557.70 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510005860 |
NUCYNTA ER, 50mg, tablet, 60 pack |
01/01/2022 |
74.47 |
570.93 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
451.74 |
411.05 |
2011 |
145.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510010010 |
NUCYNTA, 100mg, tablet, 100 pack |
01/01/2022 |
179.47 |
1375.96 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1088.71 |
990.64 |
2009 |
265.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510005010 |
NUCYNTA, 50mg, tablet, 100 pack |
01/01/2022 |
115.25 |
883.59 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
699.13 |
636.15 |
2009 |
170.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510007510 |
NUCYNTA, 75mg, tablet, 100 pack |
01/01/2022 |
134.66 |
1032.39 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
816.86 |
743.28 |
2009 |
199.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510011510 |
XTAMPZA ER, 13.5mg, capsule, 100 pack |
01/01/2022 |
78.44 |
870.73 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510012010 |
XTAMPZA ER, 18mg, capsule, 100 pack |
01/01/2022 |
99.47 |
1104.23 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510013010 |
XTAMPZA ER, 27mg, capsule, 100 pack |
01/01/2022 |
138.37 |
1536.08 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510014010 |
XTAMPZA ER, 36mg, capsule, 100 pack |
01/01/2022 |
170.32 |
1890.68 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2022 |
24510011010 |
XTAMPZA ER, 9mg, capsule, 100 pack |
01/01/2022 |
53.29 |
591.60 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000184 |
Cosette Pharmaceuticals, Inc. |
03/31/2022 |
00713016612 |
MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg |
01/28/2022 |
185.20 |
2039.10 |
None |
Single Source Drug |
3360 |
None |
Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio. |
None |
1 |
None |
06/28/2019 |
Horizon Therapeutics PLC |
None |
1 |
non-Public |
842.76 |
766.80 |
1983 |
0.01 |
None |
WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W. |
| Rx0000062 |
Covis Pharma |
03/31/2022 |
00310080039 |
Tudorza Pressair, 1 POUCH IN 1 CARTON > 1 INHALER IN 1 POUCH > 30 POWDER, METERED IN 1 INHALER, 400 mcg |
02/01/2022 |
25.72 |
311.46 |
03/13/2029 |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
01/04/2022 |
AstraZeneca Pharmaceuticals LP |
None |
1 |
None |
285.74 |
285.74 |
2015 |
140.70 |
None |
None |
| Rx0000062 |
Covis Pharma |
03/31/2022 |
00310080060 |
Tudorza Pressair, 1 POUCH IN 1 CARTON > 1 INHALER IN 1 POUCH > 60 POWDER, METERED IN 1 INHALER, 400 mcg |
02/01/2022 |
51.43 |
622.91 |
03/13/2029 |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
01/04/2022 |
AstraZeneca Pharmaceuticals LP |
None |
1 |
None |
571.48 |
571.48 |
2015 |
281.40 |
None |
None |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045291 |
Hizentra 10 ml (2g) - inner 2gm Solution UOM=1 EA vial |
07/01/2022 |
12.02 |
412.42 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045202 |
Hizentra 10 ml (2g) 2gm Solution UOM=1 EA vial |
07/01/2022 |
12.02 |
412.42 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045492 |
Hizentra 20 ml (4g) - inner 4gm Solution UOM=1 EA vial |
07/01/2022 |
24.04 |
824.84 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045404 |
Hizentra 20 ml (4g) 4gm Solution UOM=1 EA vial |
07/01/2022 |
24.04 |
824.84 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045190 |
Hizentra 5 ml (1g) - inner 1gm Solution UOM=1 EA vial |
07/01/2022 |
6.01 |
206.21 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045101 |
Hizentra 5 ml (1g) 1gm Solution UOM=1 EA vial |
07/01/2022 |
6.01 |
206.21 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045593 |
Hizentra 50 ml (10g) - inner 10gm Solution UOM=1 EA vial |
07/01/2022 |
42.10 |
2062.10 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000425 |
CSL Behring LLC |
09/30/2022 |
44206045510 |
Hizentra 50 ml (10g) 10gm Solution UOM=1 EA vial |
07/01/2022 |
42.10 |
2062.10 |
06/09/2032 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2022 |
66220028422 |
CALDOLOR, ready-to-use polypropylene flexible bag, 800 mg/200 mL, carton of 20 bags |
01/20/2022 |
25.36 |
441.94 |
03/16/2032 |
Single Source Drug |
115380 |
None |
Increase in Cost of goods manufacture. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2022 |
66220028708 |
CALDOLOR, single-dose vial, 800 mg/8 mL, tray of 25 vials |
01/20/2022 |
38.62 |
521.41 |
09/14/2030 |
Single Source Drug |
106300 |
None |
Increase in Cost of goods manufactured |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2022 |
66220031511 |
VIBATIV, single-dose vial, 750 mg, 1 vial |
01/20/2022 |
16.18 |
555.46 |
01/01/2027 |
Single Source Drug |
28318 |
None |
Increase in Cost of Goods manufacture. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2022 |
51267089099 |
Contrave Oral Tablet 120ct (naltrexome HCI/bupropion HCI) 8-90mg |
03/03/2022 |
321.60 |
625.20 |
07/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/27/2019 |
Nalpropion Pharmaceuticals LLC |
None |
None |
The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies. |
277.99 |
277.99 |
2014 |
199.50 |
None |
None |